Comparison 17. (3.5) Nitric oxide donors versus intracervical prostaglandins (all primiparae, unfavourable cervix).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Uterine hyperstimulation with FHR changes	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.74]
1.1 Glyceryl Trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.74]
2 Caesarean section	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.43, 1.55]
2.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.43, 1.55]
3 Serious neonatal morbidity/perinatal death	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.74]
3.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.74]
4 Cervix unfavourable/unchanged after 12‐24 hours	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	1.29 [0.59, 2.81]
4.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	1.29 [0.59, 2.81]
5 Oxytocin augmentation	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.43, 1.85]
5.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.43, 1.85]
6 Uterine hyperstimulation without FHR changes	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.14 [0.01, 2.61]
6.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.14 [0.01, 2.61]
7 Instrumental vaginal delivery	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.07, 14.95]
7.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.07, 14.95]
8 Perinatal death	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.74]
8.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.01, 7.74]
9 Maternal side effects (headache)	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	10.0 [1.40, 71.32]
9.1 Glyceryl trinitrate	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	10.0 [1.40, 71.32]